Lubiprostone: A Novel Drug to Treat Constipation

Main Article Content

Kamlesh Garg

Abstract

 Lubiprostone, a bicyclic fatty acid, is a novel drug of new class of agents called prostones. It is approved by US FDA for the treatment of chronic constipation and constipation associated irritable bowel syndrome (IBS-C). It activates specific chloride channels in the gastrointestinal tract to stimulate intestinal fluid secretion, increase gastrointestinal transit and improve symptoms of constipation. Lubiprostone is well tolerated in majority of the patients with nausea being the most common adverse effect. Lubiprostone represents a new approach of treatment in cases of resistant or intolerable cases of chronic constipation with proven efficacy and safety.

Key words: Lubiprostone, chronic constipation, IBS-C, spontaneous bowel movement.

Article Details

How to Cite
Garg, K. (2013). Lubiprostone: A Novel Drug to Treat Constipation. Journal of Drug Discovery And Therapeutics, 1(02). Retrieved from http://jddt.in/index.php/jddt/article/view/17
Section
Review Articles
Author Biography

Kamlesh Garg, Assistant Professor Department of Pharmacology 6th Floor, VMMC and Safdarjung Hospital New Delhi 29

Assistant Professor

Department of Pharmacology

References

REFERENCES:
1. Mizumori M, A kiba Y, Kaunitz JD. Lubiprostone stimulates duodenal bicarbonate secretion in rats. Dig Dis Sci 2009;54:2063-69.
2. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double blind, randomized, placebo-controlled trial of Lubiprostone. A locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170-77.
3. Higgins PD and Johanson JF. Epidemiology of constipation in North America: a systemic review. Am J Gastroenterol 2004;99:750-59.
4. Lacy BE and Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clinical interventions in aging 2008;3(2):357-64.
5. Selby W and Corte C. Managing constipation in adults. Australian Prescriber 2010; 33(4):116-19.
6. Lunsford TN and Harris LA. Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. International journal of women’s health 2010;2:361-74.
7. Lacy BE and Lebanon NH. Lubiprostone for chronic constipation. Gastroenterology & Hepatology 2006;2(7):483.
8. Carter NJ and Scott LJ. Lubiprostone: in constipation-predominant irritable bowel syndrome. Drugs 2009; 69(9):1229-37.
9. Moeser AJ, Nighot PK, Roerig B, Ueno R, Blikslager AT. Comparison of the chloride channel activator lubiprostone and the oral laxative polyethylene glycol 3350 on mucosal barrier repair in ischaemic-injured porcine intestine.World journal of gastroenterology 2008;14(39):6012-17.
10. Barish CF, D rossman D, Johanson JF, Ueno R. Efficacy and Safety of Lubiprostone in patients with chronic constipation.Dig Dis Sci 2010;55:1090-97.
11. Johanson JF and Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25:1351-61.
12. Johanson JF, Gargano MA, Patchen ML, Ueno R. Multi-centric open label study of Lubiprostone for the treatment of chronic constipation. Am J Gastroenterol 2005;100(9):S331.
13. Johanson JF, Gargano MA, Patchen ML, Ueno R. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterol 2004;126 (4 Suppl 2):S100.
14. Ueno R, Joswick TR, Wahle A. Efficacy and safety of Lubiprostone for the treatment of chronic constipation in males vs. females subjects. Gastroenterol 2006a;130:A322.
15. Johanson JF, Drossman DA, Panas R, Waahle A, Ueno R. Clinical trial: phase 2 study of Lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-96.
16. Drossman DA, Chey WD, Scott C, Panas R, Ueno R. Health-related quality of life in adults with irritable bowel syndrome with constipation: results of combined analysis of two phase 3 studies with Lubiprostone. Gastroenterology 2008;134 (4 suppl 1): A469.
17. Drossman DA, Chey WD, Johanson JF. Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo controlled studies. Aliment Pharmacol Ther 2009;29(3):329